-+ 0.00%
-+ 0.00%
-+ 0.00%

Wolfe Research Upgrades Vertex Pharmaceuticals to Outperform, Announces $548 Price Target

Benzinga·01/06/2026 13:17:53
Listen to the news
Wolfe Research analyst Andy Chen upgrades Vertex Pharmaceuticals (NASDAQ:VRTX) from Peer Perform to Outperform and announces $548 price target.